22091-38-9

Basic information

• Product Name: Oxazole, 2-(4-bromophenyl)-4-(chloromethyl)-
• CAS NO: 22091-38-9
• Molecular Formula: C10H7BrClNO
• Molecular Weight: 272.529
• Mol File: 22091-38-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Oxazole, 2-(4-bromophenyl)-4-(chloromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Oxazole, 2-(4-bromophenyl)-4-(chloromethyl)-(22091-38-9)
• EPA Substance Registry System: Oxazole, 2-(4-bromophenyl)-4-(chloromethyl)-(22091-38-9)

Safety Data

• Hazardous Substances Data: 22091-38-9(Hazardous Substances Data)

Upstream product

• 698-67-9 p-bromobenzamide 
• 534-07-6 1,3-Dichloroacetone 
• 36841-48-2 2-(4-bromophenyl)-4-hydroxymethyloxazole 
• 1239589-17-3 methyl 2-(4-bromophenyl)-1,3-oxazole-4-carboxylate 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 55327-32-7 2-(4-bromo-phenyl)-oxazole-4-carbaldehyde 
• 36841-54-0 5-bromo-2-(4-bromo-phenyl)-4-chloromethyl-oxazole 
• 36841-63-1 2-(4-bromo-3-nitro-phenyl)-4-chloromethyl-oxazole 
• 36841-48-2 2-(4-bromophenyl)-4-hydroxymethyloxazole 
• 33162-11-7 2-(4-bromo-phenyl)-4-iodomethyl-oxazole 
• 22087-29-2 2-(2-(4-bromophenyl)oxazol-4-yl)acetonitrile 
• 876617-48-0 2-(4-bromo-phenyl)-4-pyrrolidin-1-ylmethyI-oxazole 
• 36841-65-3 5-bromo-2-(4-bromo-3-nitro-phenyl)-4-chloromethyl-oxazole 
• 59398-95-7 5-bromo-2-(4-bromo-phenyl)-oxazole-4-carbaldehyde 
• 36841-59-5 [5-bromo-2-(4-bromo-phenyl)-oxazol-4-yl]-methanol 
• 33249-83-1 1-[2-(4-bromo-phenyl)-oxazol-4-ylmethyl]-1,3,5,7-tetraaza-adamantanium; chloride 

Relevant articles and documents

Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB

A high-throughput screening effort on 45,000 compounds resulted in the discovery of a disubstituted oxazole as a new structural class inhibitor of Mycobacterium tuberculosis (Mtb). In order to improve the activity and investigate the SAR of this scaffold, a series of disubstituted azole analogues have been designed and synthesized. The newly synthesized compounds 1a-y were evaluated for their in vitro anti-TB activity versus replicating, multi- and extensive drug resistant Mtb strains. All the compounds, except 1o, 1p and 1q, showed potent anti-TB activity with MIC of 1-64 mg/L. The test of broad spectrum panel revealed that this series are specific to Mtb. The cytotoxicity assessment indicated that the compounds were not cytotoxic against HEK 293 cells. The compounds could have a novel mechanism to anti-Mtb as they can inhibit drug sensitive and drug resistant Mtb.

OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently -(C1-C7) alkyl(optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence -H, -halogen, or -CH3.